Related Experiment Video
Updated: Apr 19, 2026
05:58
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
4.5K
Amiodarone-induced thyrotoxic thyroiditis: a diagnostic and therapeutic challenge
Umang Barvalia1, Barkha Amlani1, Ram Pathak2
1Department of Internal Medicine, Marshfield Clinic, 1000 N. Oak Avenue, Marshfield, WI 54449, USA.
Case Reports in Medicine
|December 6, 2014
Summary
Amiodarone can cause thyroid problems, including hyperthyroidism. This study details a case of type 2 amiodarone-induced hyperthyroidism and reviews diagnostic and treatment strategies.
Area of Science:
- Endocrinology
- Cardiology
Background:
- Amiodarone, an antiarrhythmic drug, structurally resembles thyroxine and frequently causes thyroid dysfunction.
- Thyroid abnormalities associated with amiodarone range from subclinical alterations to overt hypothyroidism or hyperthyroidism.
- Amiodarone-induced thyrotoxicosis (AIT) presents as Type 1 (excessive synthesis) or Type 2 (thyroid inflammation).
Purpose of the Study:
- To describe a case of amiodarone-induced type 2 hyperthyroidism.
- To review current literature on diagnostic and treatment approaches for AIT.
Main Methods:
- Case report presentation.
- Literature review of diagnostic and treatment strategies for amiodarone-induced thyrotoxicosis.
Main Results:
- Amiodarone can lead to two distinct types of thyrotoxicosis, Type 1 and Type 2, with different underlying mechanisms.
- Distinguishing between Type 1 and Type 2 AIT is crucial due to differing treatment implications.
- Mixed presentations of AIT can pose diagnostic and therapeutic challenges.
Conclusions:
- Accurate diagnosis of amiodarone-induced hyperthyroidism subtypes is essential for effective management.
- Optimal treatment strategies depend on differentiating between Type 1 and Type 2 AIT.
- Further research into managing mixed AIT presentations is warranted.
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
3.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
3.0K
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:27Hyperthyroidism II: Pathophysiology
7
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
7
01:25Hyperthyroidism I: Introduction
6
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
6
01:25Dysrhythmias VI: Management of Dysrhythmias
650
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
650
01:27Myocarditis II: Clinical Features and Diagnostic Tests
472
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
472